Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 2c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $14.42 million versus the consensus estimate of $11.96 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• William Blair on TransMedics Group (TMDX): 'We believe TransMedics’ second-quarter sales will exceed consensus estimates'
• Spacex Developed Prototype Of Handset-like Device - WSJ
• BMO Capital on Meta Platforms Inc. (META): 'incrementally positive on the shift towards an ROI-generating business'